Explore the words cloud of the PhenoSwitch project. It provides you a very rough idea of what is the project "PhenoSwitch" about.
The following table provides information about the project.
Coordinator |
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Organization address contact info |
Coordinator Country | Israel [IL] |
Project website | https://shakedlab.net.technion.ac.il/ |
Total cost | 1˙906˙250 € |
EC max contribution | 1˙906˙250 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2017-COG |
Funding Scheme | ERC-COG |
Starting year | 2018 |
Duration (year-month-day) | from 2018-04-01 to 2023-03-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY | IL (HAIFA) | coordinator | 1˙906˙250.00 |
The limited success of cancer therapy especially in advanced metastatic disease warrants a reassessment, especially given our limited understanding of the nature of cancer cells and the factors that allow them to proliferate and metastasise. Stromal cells of the tumour microenvironment, including fibroblasts, endothelial, immune, adipose and mesenchymal cells, significantly affect cancer cell characteristics and tumour fate; however, their sometimes dichotomous function in high- and low-aggressive tumours has not been thoroughly investigated. Here, we propose to elucidate the largely unknown role of haematopoietic stem and/or progenitor cells (HSCs) on tumour growth and metastases. We found that such cells reside in the tumour niche predominantly in non-aggressive tumours. We hypothesise that cancer cells trigger the differentiation of HSCs into haematopoietic tumour-supporting stromal cells, thereby inducing a phenotypic and functional switch that skews them towards a tumour-promoting phenotype, hence promoting tumour cell aggressiveness and metastases. To test our hypothesis, we will use high-throughput technologies to track the lineage, differentiation and commitment of HSCs during tumour progression. Our specific aims are therefore: (a) To systematically analyse tumour-promoting and tumour-restricting stromal phenotypes at the cellular and molecular levels. (b) To characterise stromal cell plasticity and the contribution of tumour cells to the phenotype switch. (c) To determine whether differentiated stromal cells and HSCs in cancer patients can predict clinical outcome. (d) To screen for molecules that inhibit the tumour-promoting stromal switch. Blocking the tumour-promoting phenotypic switch and maintaining a pre-mature tumour-restricting stromal microenvironment represent a novel strategy in the fight against cancer. This study will lead to the development of new tools to predict prognosis and pharmacological strategies to restrict tumour growth.
year | authors and title | journal | last update |
---|---|---|---|
2019 |
Yuval Shaked The pro-tumorigenic host response to cancer therapies published pages: 667-685, ISSN: 1474-175X, DOI: 10.1038/s41568-019-0209-6 |
Nature Reviews Cancer 19/12 | 2020-01-29 |
2019 |
Michael Timaner, Kelvin K Tsai, Yuval Shaked The multifaceted role of mesenchymal stem cells in cancer published pages: , ISSN: 1044-579X, DOI: 10.1016/j.semcancer.2019.06.003 |
Seminars in Cancer Biology | 2020-01-29 |
2019 |
Kelvin K. Tsai, Tze-Sian Chan, Yuval Shaked Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks published pages: 702, ISSN: 2077-0383, DOI: 10.3390/jcm8050702 |
Journal of Clinical Medicine 8/5 | 2020-01-29 |
2019 |
Michael Timaner, Yuval Shaked Elucidating the roles of ASPM isoforms reveals a novel prognostic marker for pancreatic cancer published pages: , ISSN: 0022-3417, DOI: 10.1002/path.5355 |
The Journal of Pathology | 2020-01-29 |
2019 |
Shimrit Avraham, Ben Korin, Sharon Aviram, Dvir Shechter, Yuval Shaked, Ami Aronheim ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription published pages: 3812-3823, ISSN: 0950-9232, DOI: 10.1038/s41388-019-0692-y |
Oncogene 38/20 | 2020-01-29 |
2019 |
Michael Timaner, Ruslana Kotsofruk, Ziv Raviv, Ksenia Magidey, Dvir Shechter, Tal Kan, Alexander Nevelsky, Shahar Daniel, Elisabeth G. E. de Vries, Tongwu Zhang, Orit Kaidar-Person, Robert S. Kerbel, Yuval Shaked Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1 published pages: , ISSN: 0950-9232, DOI: 10.1038/s41388-019-0971-7 |
Oncogene | 2020-01-29 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PHENOSWITCH" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PHENOSWITCH" are provided by the European Opendata Portal: CORDIS opendata.